Sodium Valproate Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Antiepileptic
Subclass
Broad-spectrum anticonvulsant (valproate group)
Speciality
Neurology
Schedule (India)
Schedule H
Routes
Oral, Intravenous
Formulations
- Oral tablets: 200 mg, 300 mg, 500 mg
- Oral controlled-release tablets: 200 mg CR, 300 mg CR, 500 mg CR
- Oral syrup: 200 mg/5 mL
- Injection (IV): 100 mg/mL (5 mL vial = 500 mg)
- Note: Valproate semisodium (divalproex sodium) also available — refer separate entry
Adult indications
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Epilepsy — Generalised and Focal Seizures
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 10–15 mg/kg/day orally in 2–3 divided doses |
| Titration | Increase by 5–10 mg/kg every 5–7 days based on response |
| Usual maintenance dose | 20–30 mg/kg/day |
| Maximum dose | 60 mg/kg/day (specialist supervision for refractory cases) |
Clinical notes:
- CR formulations preferred for once or twice daily dosing and improved tolerability
- Target therapeutic plasma level: 50–100 μg/mL
- Syrup formulation useful for dose flexibility
2. Status Epilepticus (IV) — When first-line agents fail
Adults:
| Parameter | Recommendation |
|---|---|
| Loading dose | 20–40 mg/kg IV over 10–15 minutes |
| Maintenance | 1–2 mg/kg/hour continuous infusion OR transition to oral when feasible |
| Maximum infusion rate | 6 mg/kg/min |
Clinical notes:
- Specialist/ICU setting only
- Avoid rapid bolus to reduce hypotension risk
- Alternative when phenytoin contraindicated
3. Bipolar Disorder — Acute Mania
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 750–1000 mg/day orally in 2–3 divided doses |
| Titration | Increase by 250–500 mg every 3–5 days |
| Usual maintenance dose | 1000–2000 mg/day |
| Maximum dose | 60 mg/kg/day |
| Target plasma level | 50–125 μg/mL |
Clinical notes:
- Not recommended for maintenance monotherapy in bipolar disorder
- Avoid in women of childbearing potential unless pregnancy prevention programme in place
Secondary Indications — Adults Only (Off-label)
| Indication | Dose | Duration | Notes |
|---|---|---|---|
| Migraine prophylaxis — OFF-LABEL | 500–1000 mg/day in divided doses | 3–6 months trial | Specialist initiation; supported by RCT evidence; avoid in women of childbearing age |
| Behavioural disturbance in dementia — OFF-LABEL | 250–500 mg/day | Variable | Specialist-only; limited evidence; use with extreme caution in frail elderly |
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indications
1. Epilepsy — Generalised and Focal Seizures
Age: ≥1 month
| Weight | Starting Dose | Maintenance Dose | Maximum Dose |
|---|---|---|---|
| <20 kg | 10–15 mg/kg/day in 2–3 divided doses | 20–30 mg/kg/day | 40 mg/kg/day |
| ≥20 kg | 300–600 mg/day in 2–3 divided doses | 20–35 mg/kg/day | 60 mg/kg/day (refractory cases) |
Clinical notes:
- Use syrup formulation for accurate dosing in infants and young children
- Titrate by 5–10 mg/kg/week
- Target plasma levels: 50–100 μg/mL
2. Status Epilepticus (IV)
Paediatric Neurologist supervision mandatory
| Parameter | Recommendation |
|---|---|
| Loading dose | 20–30 mg/kg IV over 10–15 minutes |
| Maintenance | 1–2 mg/kg/hour IV OR transition to oral |
Secondary Indications — Paediatrics (Off-label)
Not routinely recommended for off-label indications in paediatric population.
Paediatric Safety Alert
⚠️ Avoid use in children <2 years unless absolutely essential and under specialist supervision — significantly increased risk of fatal hepatotoxicity, particularly with:
- Polytherapy with other antiepileptics
- Underlying metabolic disorders
- Developmental delay
Renal Adjustments
| Renal Function | Recommendation |
|---|---|
| Mild–Moderate impairment | No dosage adjustment required |
| Severe impairment/Dialysis | Monitor free (unbound) valproate levels; total levels may be misleading due to decreased protein binding |
| Haemodialysis | Valproate is not significantly dialysed; supplemental dosing generally not required |
Hepatic adjustment
Contraindications
- Active liver disease or significant hepatic dysfunction
- Family history of severe hepatic dysfunction (especially drug-related)
- Known hypersensitivity to valproate or any excipient
- Urea cycle disorders (risk of hyperammonaemic encephalopathy)
- Known mitochondrial disorders caused by POLG mutations
- Porphyria
- Women of childbearing potential for psychiatric indications or migraine (unless adequate contraception and informed consent)
Cautions
- Age <2 years — highest risk of fatal hepatotoxicity
- Concomitant use with other antiepileptics (increased hepatotoxicity and ADR risk)
- Elderly — increased sensitivity, fall risk, cognitive effects
- Pre-existing thrombocytopenia or bleeding disorders
- History of pancreatitis
- Systemic lupus erythematosus
- Renal impairment (monitor free drug levels)
- Patients at risk of suicidal ideation — monitor closely
- Before elective surgery — assess bleeding risk
Pregnancy'
| Aspect | Guidance |
|---|---|
| Overall risk | High teratogenic potential — neural tube defects (1–2%), craniofacial abnormalities, developmental delay, autism spectrum disorder |
| Epilepsy indication | Avoid if safer alternatives exist; if essential, use lowest effective dose as monotherapy (preferably <1000 mg/day) |
| Psychiatric/Migraine indication |
CONTRAINDICATED
|
| Preconception | High-dose folic acid (5 mg/day) at least 3 months prior |
| Monitoring | Detailed anomaly scan at 18–20 weeks; serial growth scans |
| Counselling | Mandatory informed consent regarding teratogenic risks before initiating in any woman of childbearing potential |
Lactation
| Aspect | Guidance |
|---|---|
| Compatibility | Generally compatible with breastfeeding |
| Excretion in milk | Low (1–10% of maternal serum concentration) |
| Infant monitoring | Observe for excessive sedation, poor feeding, jaundice |
| Preferred alternative | If mother requires valproate for epilepsy, breastfeeding acceptable with monitoring |
Elderly
| Aspect | Recommendation |
|---|---|
| Starting dose | 250–500 mg/day |
| Titration | Slow (increase every 5–7 days) |
| Cautions | Increased risk of sedation, tremor, gait instability, falls |
| Monitoring | Baseline and periodic LFTs, platelet count; monitor for encephalopathy symptoms |
| Special considerations | Risk of SIADH-like hyponatraemia (rare); cognitive impairment may be exacerbated |
Major drug interactions
| Interacting Drug | Effect | Management |
|---|---|---|
| Lamotrigine | Valproate inhibits lamotrigine metabolism — markedly increased lamotrigine levels and risk of serious rash (SJS/TEN) | Reduce lamotrigine dose by 50% |
| Carbapenem antibiotics (meropenem, imipenem) | Rapid and significant reduction in valproate levels (up to 60–90%) |
Avoid combination; use alternative antibiotic or AED
|
| Topiramate | Additive risk of hyperammonaemia and encephalopathy | Monitor ammonia levels; avoid if possible |
| Phenytoin | Mutual interaction — unpredictable changes in levels of both | Monitor levels of both drugs; dose adjustment likely needed |
| Carbamazepine | Enzyme induction decreases valproate levels | May need to increase valproate dose; monitor levels |
| Warfarin | Valproate displaces warfarin from protein binding — increased bleeding risk | Monitor INR closely; adjust warfarin dose |
Moderate drug interactions
| Interacting Drug | Effect | Management |
|---|---|---|
| Aspirin (high-dose) | Increased free valproate fraction; increased toxicity risk | Use with caution, especially in children |
| Benzodiazepines | Additive CNS depression | Monitor for excessive sedation |
| Rifampicin | May reduce valproate efficacy via enzyme induction | Monitor clinical response and serum levels |
| Cholestyramine | Reduced valproate absorption | Separate administration by at least 3 hours |
| Cimetidine | Inhibits valproate metabolism; increased levels | Monitor for toxicity |
| Erythromycin | May increase valproate levels | Monitor |
Common Adverse effects
- Nausea, vomiting, dyspepsia
- Weight gain
- Tremor (dose-related)
- Transient hair loss (reversible on dose reduction)
- Drowsiness, lethargy
- Asymptomatic elevation of liver transaminases
- Peripheral oedema
Serious Adverse effects
| Adverse Effect | Clinical Notes |
|---|---|
| Hepatotoxicity | Highest risk in children <2 years, polytherapy, metabolic disorders; can be fatal; monitor LFTs; discontinue if symptomatic liver dysfunction |
| Pancreatitis | Can occur at any time; may be fatal; discontinue immediately if suspected |
| Thrombocytopenia | Dose-related; check platelet count if bruising or bleeding |
| Hyperammonaemic encephalopathy | Altered consciousness, lethargy, vomiting; can occur without LFT abnormalities; check ammonia levels |
| Severe cutaneous reactions | SJS/TEN (rare); discontinue immediately |
| Teratogenicity | Neural tube defects, developmental delay — see Pregnancy section |
Monitoring requirements
| Phase | Parameters |
|---|---|
| Baseline | LFTs, CBC with platelets, serum ammonia (if symptoms), coagulation profile, pregnancy test (if applicable) |
| During titration | LFTs and CBC at 2–4 weeks |
| Therapeutic drug monitoring | Target: 50–100 μg/mL (epilepsy); 50–125 μg/mL (mania); check if toxicity suspected, non-response, or drug interactions |
| Long-term | LFTs and CBC every 3–6 months |
| Special populations | More frequent monitoring in children <2 years, elderly, hepatic impairment |
Brands in India
- Encorate®, Encorate Chrono® (Sun Pharma)
- Valparin®, Valparin Chrono® (Sanofi)
- Epilex®, Epilex Chrono® (Abbott)
- Valance® (Intas)
- Sodival® (Micro Labs)
- Multiple generic formulations widely available
Price range (INR)
| Formulation | Approximate Price |
|---|---|
| Tablets 200 mg | ₹2–4 per tablet |
| Tablets 500 mg | ₹4–8 per tablet |
| CR tablets 300 mg | ₹5–10 per tablet |
| CR tablets 500 mg | ₹8–15 per tablet |
| Syrup 200 mg/5 mL (100 mL) | ₹25–50 per bottle |
| Injection 500 mg/5 mL | ₹60–120 per vial |
Note: Not currently on NLEM 2022 for psychiatric indications; included for epilepsy.
Clinical pearls
- Hepatotoxicity risk is highest in children <2 years on polytherapy — avoid unless no alternatives; monitor LFTs rigorously
- Mandatory pregnancy counselling — all women of childbearing potential must be counselled about teratogenic risks before initiation; document informed consent
- CR formulations improve compliance and reduce peak-related adverse effects (tremor, sedation)
- Tremor and hair loss are dose-dependent — often improve with dose reduction or zinc supplementation (for hair loss)
- IV valproate is a useful second-line agent in status epilepticus when phenytoin is contraindicated (cardiac disease, hypotension)
- Avoid carbapenem antibiotics in patients on valproate — dramatic reduction in levels can precipitate seizures
- Check ammonia levels if unexplained lethargy or confusion develops, even with normal LFTs
Version
RxIndia v1.0 — 04 May 2025
Reference
- CDSCO approved prescribing information
- National Formulary of India (NFI) 2021
- Indian Epilepsy Society Guidelines
- NIMHANS Psychiatry Protocols
- API Textbook of Medicine
- AIIMS Neurology Protocols
- IAP Guidelines (Paediatric dosing)
- ICMR Guidelines for Reproductive Health (teratogenicity)
- Published RCTs/meta-analyses (migraine prophylaxis — off-label basis)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.